Storm of soluble immune checkpoints associated with disease severity of COVID-19.
Identifieur interne : 000320 ( Main/Corpus ); précédent : 000319; suivant : 000321Storm of soluble immune checkpoints associated with disease severity of COVID-19.
Auteurs : Yaxian Kong ; Yu Wang ; Xueying Wu ; Junyan Han ; Guoli Li ; Mingxi Hua ; Kai Han ; Henghui Zhang ; Ang Li ; Hui ZengSource :
- Signal transduction and targeted therapy [ 2059-3635 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Biomarkers (blood), Coronavirus Infections (diagnosis), Coronavirus Infections (genetics), Coronavirus Infections (immunology), Coronavirus Infections (mortality), Cytokine Release Syndrome (diagnosis), Cytokine Release Syndrome (genetics), Cytokine Release Syndrome (immunology), Cytokine Release Syndrome (mortality), Disease Progression (MeSH), Female (MeSH), Gene Expression Regulation (immunology), Hepatitis A Virus Cellular Receptor 2 (blood), Hepatitis A Virus Cellular Receptor 2 (genetics), Hepatitis A Virus Cellular Receptor 2 (immunology), Humans (MeSH), Indoleamine-Pyrrole 2,3,-Dioxygenase (blood), Indoleamine-Pyrrole 2,3,-Dioxygenase (genetics), Indoleamine-Pyrrole 2,3,-Dioxygenase (immunology), Lymphocyte Count (MeSH), Lymphopenia (diagnosis), Lymphopenia (genetics), Lymphopenia (immunology), Lymphopenia (mortality), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (genetics), Pneumonia, Viral (immunology), Pneumonia, Viral (mortality), Retrospective Studies (MeSH), Severity of Illness Index (MeSH), Survival Analysis (MeSH), T-Lymphocytes (immunology), T-Lymphocytes (virology), Tumor Necrosis Factor Receptor Superfamily, Member 7 (blood), Tumor Necrosis Factor Receptor Superfamily, Member 7 (genetics), Tumor Necrosis Factor Receptor Superfamily, Member 7 (immunology), Tumor Necrosis Factor Receptor Superfamily, Member 9 (blood), Tumor Necrosis Factor Receptor Superfamily, Member 9 (genetics), Tumor Necrosis Factor Receptor Superfamily, Member 9 (immunology).
- MESH :
- chemical , blood : Biomarkers, Hepatitis A Virus Cellular Receptor 2, Indoleamine-Pyrrole 2,3,-Dioxygenase, Tumor Necrosis Factor Receptor Superfamily, Member 7, Tumor Necrosis Factor Receptor Superfamily, Member 9.
- diagnosis : Coronavirus Infections, Cytokine Release Syndrome, Lymphopenia, Pneumonia, Viral.
- genetics : Coronavirus Infections, Cytokine Release Syndrome, Hepatitis A Virus Cellular Receptor 2, Indoleamine-Pyrrole 2,3,-Dioxygenase, Lymphopenia, Pneumonia, Viral, Tumor Necrosis Factor Receptor Superfamily, Member 7, Tumor Necrosis Factor Receptor Superfamily, Member 9.
- immunology : Betacoronavirus, Coronavirus Infections, Cytokine Release Syndrome, Gene Expression Regulation, Hepatitis A Virus Cellular Receptor 2, Indoleamine-Pyrrole 2,3,-Dioxygenase, Lymphopenia, Pneumonia, Viral, T-Lymphocytes, Tumor Necrosis Factor Receptor Superfamily, Member 7, Tumor Necrosis Factor Receptor Superfamily, Member 9.
- mortality : Coronavirus Infections, Cytokine Release Syndrome, Lymphopenia, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- virology : T-Lymphocytes.
- Adult, Aged, Aged, 80 and over, Disease Progression, Female, Humans, Lymphocyte Count, Male, Middle Aged, Pandemics, Retrospective Studies, Severity of Illness Index, Survival Analysis.
DOI: 10.1038/s41392-020-00308-2
PubMed: 32895366
PubMed Central: PMC7475713
Links to Exploration step
pubmed:32895366Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Storm of soluble immune checkpoints associated with disease severity of COVID-19.</title>
<author><name sortKey="Kong, Yaxian" sort="Kong, Yaxian" uniqKey="Kong Y" first="Yaxian" last="Kong">Yaxian Kong</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Yu" sort="Wang, Yu" uniqKey="Wang Y" first="Yu" last="Wang">Yu Wang</name>
<affiliation><nlm:affiliation>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wu, Xueying" sort="Wu, Xueying" uniqKey="Wu X" first="Xueying" last="Wu">Xueying Wu</name>
<affiliation><nlm:affiliation>Immupeutics Medicine Institute, Beijing, 100191, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Han, Junyan" sort="Han, Junyan" uniqKey="Han J" first="Junyan" last="Han">Junyan Han</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Guoli" sort="Li, Guoli" uniqKey="Li G" first="Guoli" last="Li">Guoli Li</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hua, Mingxi" sort="Hua, Mingxi" uniqKey="Hua M" first="Mingxi" last="Hua">Mingxi Hua</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Han, Kai" sort="Han, Kai" uniqKey="Han K" first="Kai" last="Han">Kai Han</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Henghui" sort="Zhang, Henghui" uniqKey="Zhang H" first="Henghui" last="Zhang">Henghui Zhang</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhhbao@ccmu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Ang" sort="Li, Ang" uniqKey="Li A" first="Ang" last="Li">Ang Li</name>
<affiliation><nlm:affiliation>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zeng, Hui" sort="Zeng, Hui" uniqKey="Zeng H" first="Hui" last="Zeng">Hui Zeng</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32895366</idno>
<idno type="pmid">32895366</idno>
<idno type="doi">10.1038/s41392-020-00308-2</idno>
<idno type="pmc">PMC7475713</idno>
<idno type="wicri:Area/Main/Corpus">000320</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000320</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Storm of soluble immune checkpoints associated with disease severity of COVID-19.</title>
<author><name sortKey="Kong, Yaxian" sort="Kong, Yaxian" uniqKey="Kong Y" first="Yaxian" last="Kong">Yaxian Kong</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Yu" sort="Wang, Yu" uniqKey="Wang Y" first="Yu" last="Wang">Yu Wang</name>
<affiliation><nlm:affiliation>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wu, Xueying" sort="Wu, Xueying" uniqKey="Wu X" first="Xueying" last="Wu">Xueying Wu</name>
<affiliation><nlm:affiliation>Immupeutics Medicine Institute, Beijing, 100191, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Han, Junyan" sort="Han, Junyan" uniqKey="Han J" first="Junyan" last="Han">Junyan Han</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Guoli" sort="Li, Guoli" uniqKey="Li G" first="Guoli" last="Li">Guoli Li</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hua, Mingxi" sort="Hua, Mingxi" uniqKey="Hua M" first="Mingxi" last="Hua">Mingxi Hua</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Han, Kai" sort="Han, Kai" uniqKey="Han K" first="Kai" last="Han">Kai Han</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Henghui" sort="Zhang, Henghui" uniqKey="Zhang H" first="Henghui" last="Zhang">Henghui Zhang</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhhbao@ccmu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Ang" sort="Li, Ang" uniqKey="Li A" first="Ang" last="Li">Ang Li</name>
<affiliation><nlm:affiliation>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zeng, Hui" sort="Zeng, Hui" uniqKey="Zeng H" first="Hui" last="Zeng">Hui Zeng</name>
<affiliation><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Signal transduction and targeted therapy</title>
<idno type="eISSN">2059-3635</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Biomarkers (blood)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (genetics)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Cytokine Release Syndrome (diagnosis)</term>
<term>Cytokine Release Syndrome (genetics)</term>
<term>Cytokine Release Syndrome (immunology)</term>
<term>Cytokine Release Syndrome (mortality)</term>
<term>Disease Progression (MeSH)</term>
<term>Female (MeSH)</term>
<term>Gene Expression Regulation (immunology)</term>
<term>Hepatitis A Virus Cellular Receptor 2 (blood)</term>
<term>Hepatitis A Virus Cellular Receptor 2 (genetics)</term>
<term>Hepatitis A Virus Cellular Receptor 2 (immunology)</term>
<term>Humans (MeSH)</term>
<term>Indoleamine-Pyrrole 2,3,-Dioxygenase (blood)</term>
<term>Indoleamine-Pyrrole 2,3,-Dioxygenase (genetics)</term>
<term>Indoleamine-Pyrrole 2,3,-Dioxygenase (immunology)</term>
<term>Lymphocyte Count (MeSH)</term>
<term>Lymphopenia (diagnosis)</term>
<term>Lymphopenia (genetics)</term>
<term>Lymphopenia (immunology)</term>
<term>Lymphopenia (mortality)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (genetics)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Survival Analysis (MeSH)</term>
<term>T-Lymphocytes (immunology)</term>
<term>T-Lymphocytes (virology)</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (blood)</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (genetics)</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (immunology)</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 9 (blood)</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 9 (genetics)</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 9 (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
<term>Hepatitis A Virus Cellular Receptor 2</term>
<term>Indoleamine-Pyrrole 2,3,-Dioxygenase</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 9</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Lymphopenia</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Hepatitis A Virus Cellular Receptor 2</term>
<term>Indoleamine-Pyrrole 2,3,-Dioxygenase</term>
<term>Lymphopenia</term>
<term>Pneumonia, Viral</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 9</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Gene Expression Regulation</term>
<term>Hepatitis A Virus Cellular Receptor 2</term>
<term>Indoleamine-Pyrrole 2,3,-Dioxygenase</term>
<term>Lymphopenia</term>
<term>Pneumonia, Viral</term>
<term>T-Lymphocytes</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term>
<term>Tumor Necrosis Factor Receptor Superfamily, Member 9</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Lymphopenia</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphocyte Count</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Survival Analysis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32895366</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>09</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>Signal transduction and targeted therapy</Title>
<ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Storm of soluble immune checkpoints associated with disease severity of COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>192</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-020-00308-2</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kong</LastName>
<ForeName>Yaxian</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Xueying</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Immupeutics Medicine Institute, Beijing, 100191, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Han</LastName>
<ForeName>Junyan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Guoli</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hua</LastName>
<ForeName>Mingxi</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Han</LastName>
<ForeName>Kai</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Henghui</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhhbao@ccmu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Ang</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zeng</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<Identifier Source="ORCID">0000-0002-7456-6061</Identifier>
<AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>ZYLX201802</GrantID>
<Agency>Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Signal Transduct Target Ther</MedlineTA>
<NlmUniqueID>101676423</NlmUniqueID>
<ISSNLinking>2059-3635</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C448908">HAVCR2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000072597">Hepatitis A Virus Cellular Receptor 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505714">TNFRSF9 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018127">Tumor Necrosis Factor Receptor Superfamily, Member 7</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053261">Tumor Necrosis Factor Receptor Superfamily, Member 9</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C576710">indoleamine 2,3-dioxygenase 1, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072597" MajorTopicYN="N">Hepatitis A Virus Cellular Receptor 2</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018127" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 7</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053261" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 9</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>07</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>19</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32895366</ArticleId>
<ArticleId IdType="doi">10.1038/s41392-020-00308-2</ArticleId>
<ArticleId IdType="pii">10.1038/s41392-020-00308-2</ArticleId>
<ArticleId IdType="pmc">PMC7475713</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2020 Aug 18;53(2):442-455.e4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32668194</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunother Cancer. 2018 Nov 27;6(1):132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30482248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Aug;26(8):1218-1223</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32581323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2020 May;17(5):541-543</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32203186</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32895366 |texte= Storm of soluble immune checkpoints associated with disease severity of COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32895366" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |